Penumbra Inc (PEN) Stock
Key stats
- Market cap
- $12.65B
- Price / Earnings ratio
- 78.5x
- EPS (TTM)
- $4.09
- Volume
- Loading
- 52-week high
- $362.41
- 52-week low
- $221.26
Source: third-party data provider, as of October 17, 2026
Compare with PEN
Recent news

IART vs. PEN: Which Stock Is the Better Value Option?
IART vs. PEN: Which Stock Is the Better Value Option?
PEN

IART or PEN: Which Is the Better Value Stock Right Now?
IART or PEN: Which Is the Better Value Stock Right Now?
PEN

Reasons to Retain Penumbra Stock in Your Portfolio for Now
Reasons to Retain Penumbra Stock in Your Portfolio for Now
PEN

TFX vs. PEN: Which Stock Is the Better Value Option?
TFX vs. PEN: Which Stock Is the Better Value Option?
PEN
News tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 58.16
- MACD 12/26/9
- -0.07
- EMA 9 of MACD
- -0.56
- MACD histogram
- 0.49
- SMA 50
- $321.22
- Price below SMA 50
- EMA 50
- $320.01
- Price above EMA 50
- SMA 200
- $327.02
- Price below SMA 200
- EMA 200
- $318.15
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of October 15, 2026. Technical data, not a recommendation.
Analyst ratings
No analyst data available
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
The market is expecting earnings per share of $1.20 for this quarter. The company has not yet shared when it is announcing earnings.
Source: third-party data provider
Latest news

IART vs. PEN: Which Stock Is the Better Value Option?
IART vs. PEN: Which Stock Is the Better Value Option?
PEN

IART or PEN: Which Is the Better Value Stock Right Now?
IART or PEN: Which Is the Better Value Stock Right Now?
PEN

Reasons to Retain Penumbra Stock in Your Portfolio for Now
Reasons to Retain Penumbra Stock in Your Portfolio for Now
PEN

TFX vs. PEN: Which Stock Is the Better Value Option?
TFX vs. PEN: Which Stock Is the Better Value Option?
PEN

TFX or PEN: Which Is the Better Value Stock Right Now?
TFX or PEN: Which Is the Better Value Stock Right Now?
PEN

TFX vs. PEN: Which Stock Is the Better Value Option?
TFX vs. PEN: Which Stock Is the Better Value Option?
PEN

3 Medical Device Stocks Giving Investors a Different Healthcare Play
3 Medical Device Stocks Giving Investors a Different Healthcare Play
PEN

IQV vs. PEN: Which Stock Is the Better Value Option?
IQV vs. PEN: Which Stock Is the Better Value Option?
PEN

GMED vs. PEN: Which Stock Should Value Investors Buy Now?
GMED vs. PEN: Which Stock Should Value Investors Buy Now?
PEN

Penumbra Receives CE Nod for THUNDERBOLT: Stock to Gain?
Penumbra Receives CE Nod for THUNDERBOLT: Stock to Gain?
PEN
News tone: automated (AI) classification of the article's content, not a price prediction.
About Penumbra Inc
Domiciled in the US, Penumbra designs, manufactures, and markets an array of thrombectomy and embolization devices and equipment to mechanically remove blood clots. The firm sells mainly to hospitals and physicians. These minimally invasive devices are primarily used in the acute care setting for patients with stroke, pulmonary embolism, deep vein thrombosis, cranial aneurysms, and other vascular diseases.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Adam Elsesser J.D. | Co-Founder, Chairman & CEO | 1962 |
| Ms. Maggie S. Yuen | Chief Financial Officer | 1972 |
| Ms. Shruthi Narayan | President | 1985 |
| Dr. Arani Bose M.D. | Co-Founder & Director | 1962 |
| Mr. Lambert Shiu | Chief Accounting Officer | 1980 |
| Ms. Johanna Roberts J.D. | Executive VP, General Counsel & Secretary | 1972 |
| Mr. Ben Sorci | Executive Vice President of Operations | — |
| Ms. Jee Hamlyn-Harris | Investor Relations Officer | — |
| Mr. Ben Tompkins | Executive Vice President of Development & Compliance | — |
| Mr. Jason Richard Mills | Executive Vice President of Strategy | — |
Fundamentals
Valuation
Profitability
Trading
Source: third-party data provider, as of October 17, 2026
Technical indicators
- RSI 14
- 58.16
- MACD 12/26/9
- -0.07
- EMA 9 of MACD
- -0.56
- MACD histogram
- 0.49
- SMA 50
- $321.22
- Price below SMA 50
- EMA 50
- $320.01
- Price above EMA 50
- SMA 200
- $327.02
- Price below SMA 200
- EMA 200
- $318.15
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of October 15, 2026. Technical data, not a recommendation.
Analyst views
No analyst data available
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | +4.1 | -12.1 | +18.0 | |||||||||
| 2022 | -20.4 | -2.8 | -1.0 | -24.1 | -17.1 | -11.9 | +10.9 | +16.4 | +14.0 | -12.3 | +29.4 | +5.9 |
| 2023 | +13.2 | +1.0 | +7.9 | +0.8 | +7.7 | +9.5 | -10.5 | -11.3 | -8.4 | -19.9 | +14.4 | +10.4 |
| 2024 | +3.0 | -7.6 | -5.7 | -9.6 | -7.7 | -4.3 | +7.8 | |||||
| 2025 | +7.1 | |||||||||||
| 2026 | +13.5 | -3.5 | -4.1 | -0.8 | -2.2 | -1.0 | +1.5 | +0.0 | -1.3 | +1.0 |



